Timothy John Garnett Acquires 14,124 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Timothy John Garnett purchased 14,124 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was acquired at an average price of $17.89 per share, with a total value of $252,678.36. Following the completion of the purchase, the director directly owned 14,124 shares in the company, valued at $252,678.36. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Maplight Therapeutics Stock Performance

Maplight Therapeutics stock opened at $17.22 on Friday. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $21.55. The firm’s 50 day moving average is $18.15. The company has a market capitalization of $781.32 million and a PE ratio of -0.46.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Institutional Trading of Maplight Therapeutics

A number of institutional investors have recently bought and sold shares of MPLT. Goldman Sachs Group Inc. bought a new position in Maplight Therapeutics during the fourth quarter valued at $34,026,000. Sanofi bought a new position in Maplight Therapeutics during the 4th quarter valued at about $16,020,000. Pivotal bioVenture Partners Investment Advisor LLC purchased a new stake in Maplight Therapeutics in the 4th quarter worth about $10,743,000. Velan Capital Investment Management LP bought a new stake in Maplight Therapeutics in the fourth quarter worth about $9,174,000. Finally, Siren L.L.C. purchased a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $7,904,000.

Analyst Ratings Changes

A number of equities analysts recently commented on MPLT shares. Stifel Nicolaus began coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 price target for the company. Wall Street Zen raised shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Jefferies Financial Group started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $32.00 price target on the stock. Morgan Stanley started coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set an “overweight” rating and a $34.00 price objective for the company. Finally, Leerink Partners began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.